MELBOURNE, Australia - Atisama Therapeutics, a clinical-stage biotechnology company developing splice-switching oligonucleotide therapeutics for chronic inflammatory disease, announced progress in its Phase 1 study of RB042 and the appointment of Dr. Bernard Coulie as Chair of the Board of Directors.
The Phase 1 study of RB042 in healthy volunteers and smokers has advanced to multiple ascending dose cohorts. Three of four single ascending dose cohorts are completed, and the first multiple ascending dose cohort has started. The drug has shown safety and tolerability so far. Higher-dose results are expected in the second half of 2026.
RB042 is an inhaled splice-switching oligonucleotide targeting inflammation in chronic obstructive pulmonary disease. The trial is registered as NCT07285122.
Dr. Bernard Coulie is President and CEO of Pliant Therapeutics, with previous roles at Johnson & Johnson and Actogenix.
Dr. Ed Tucker, Chief Medical Officer at Atisama, stated that safety data supports advancement into multiple ascending dose dosing.
Atisama, formerly known as Rage Bio, is headquartered in Melbourne, Australia.
